Qiagen NV (QGEN) Fair Value & Analysis
Healthcare · US · Market cap $8.5B · ISIN NL0015002CX3
What is Qiagen NV really worth?
Qiagen NV
QGEN · US
A strong business, but trading 13% above our fair value of $38.93.
Strengths
Risks
Fair value as of: Aug 29, 2026
From 26 valuation models · updated 7 days ago
Share price +3.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A fairly wide model range ($23.76 to $49.65) leaves room in how you read the outcome.
- The price sits in the upper half of our model range, so the margin of safety is thin.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.
How to read this chart
60‑month range $30.70 – $52.40 · fair‑value band $23.76 – $49.65 · the $43.86 price screens above the $38.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 29, 2026.
Analysis
Qiagen NV (QGEN) currently trades at $43.86, while our model-based Fair Value estimate is $38.93, implying the stock looks roughly 12.7% overvalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $41.42 per share, and 4 of the 26 models we run sit above the $43.86 price. Bear case: the Dividend Discount group reads lowest at $3.94, and 22 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Qiagen NV generated revenue of $2.1B at a net margin of 19.2%. Revenue grew 1.8% year over year. It earns a return on equity of 11.9%. Net debt stands at $815M. Fundamentals as of Aug 29, 2026
Our scenario range runs from $23.76 (bear case) to $49.65 (bull case); at $43.86, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −11%, QGEN screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $1.33 per share, which is 3.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings ($41.42) versus Dividend Discount ($3.94). Highest evidence: FCF DCF (79).
Notify me when QGEN reaches fair value
Put QGEN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as …
Full company description
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Qiagen NV reported revenue of $2.1B in FY2025 versus $2.3B in FY2021, a compound −1.8%/yr. Reported net income was $425M in FY2025, compounding −4.6%/yr from FY2021.
of which total revenue +4.8 % · buybacks/dilution +0.8 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
QGEN screens 13% overvalued. Compare with Thermo Fisher Scientific Inc →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market?
- Qiagen hit with $4.8M jury award in patent dispute with 10x Genomics
- QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
- Two potential buyers begin formal due diligence in Qiagen sales process - report
Peer Group
Diagnostics & Research · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| WuXi AppTec Co 2359 | HK$189.30 | HK$150.16 | −21% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| IDEXX Laboratories, Inc IDXX | $556.69 | $255.77 | −54% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
Compare Qiagen NV with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Qiagen NV (QGEN) overvalued or undervalued?
What is the fair value of QGEN?
What is the quality score of QGEN?
What is the revenue of Qiagen NV (QGEN)?
What is the net profit margin of QGEN?
Does Qiagen NV pay a dividend?
Watch Qiagen NV in the live analysis
One click puts Qiagen NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.